Accumulating evidence has underscored the m6A writer METTL3, exhibited an oncogenic potentiality in CRC tumorigenesis recently, wherein it accelerated tumor growth and metastasis through suppressing the expression of YPEL5 in an m6A-YTHDF2-dependent manner [43]. The gene discussed is METTL3; the disease is neoplasm.